Dark

Check out our Level2View

AGLE
Aeglea BioTherapeutics, Inc.
stock NASDAQ

Inactive

Nov 27, 2023

12.01USD+8.786%(+0.97)43,369

Pre-market

0.00USD-100.000%(-11.04)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 25, 2022

08:03AM EST Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on PR Newswire

Jan 5, 2022

07:02AM EST Aeglea BioTherapeutics to Participate in Two Investor Conferences in January PR Newswire

Dec 14, 2021

05:03AM EST Aeglea BioTherapeutics CEO Anthony Quinn Reported 53,634 Shares @ Avg Price of $3.71/Share in Form 4 Filing on Monday Benzinga

Dec 6, 2021

02:31PM EST Mid-Afternoon Market Update: Dow Jumps 700 Points; Del Taco Restaurants Shares Spike Higher Benzinga

12:30PM EST Mid-Day Market Update: Crude Oil Rises 3%; Aeglea BioTherapeutics Shares Plunge Benzinga

10:03AM EST Mid-Morning Market Update: Markets Mostly Higher; Science Applications International Posts Upbeat Earnings Benzinga

06:58AM EST Aeglea BioTherapeutics Inc. (AGLE) said that the pivotal Phase 3 study, PEACE or Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints, met the primary endpoint with a statistically significant reduction in plasma arginine from baseline after 24 weeks of treatment with pegzilarginase. RTTNews

06:33AM EST Aeglea BioTherapeutics Phase 3 Study Of Pegzilarginase Meets Primary Endpoint In Patients With Arginase 1 Deficiency RTTNews

06:30AM EST Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 PR Newswire

Dec 5, 2021

06:43PM EST Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency Benzinga

06:00PM EST Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline PR Newswire

Nov 16, 2021

07:03AM EST Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors PR Newswire

Nov 4, 2021

07:31AM EDT Aeglea BioTherapeutics Q3 EPS $(0.31) Down From $(0.29) YoY, Sales $1.40M Benzinga

07:25AM EDT Aeglea BioTherapeutics Q3 Net Loss Widens To $20.3 Mln From $18.0 Mln Prior Year RTTNews

07:12AM EDT Aeglea BioTherapeutics Announces Presentation Of 7 Abstracts At ICIEM 2021 Including Oral Presentation Of PEACE Study Baseline Characteristics Benzinga

07:02AM EDT Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and PR Newswire

06:59AM EDT Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 PR Newswire

Sep 1, 2021

08:30AM EDT Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021 PR Newswire

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 5, 2021

08:52AM EDT Aeglea BioTherapeutics Q2 EPS $(0.10) Up From $(0.40) YoY Benzinga

08:38AM EDT Aeglea BioTherapeutics Q2 Net Loss $6.8 Mln Vs. Net Loss $21.4 Mln Last Year RTTNews

08:38AM EDT Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and PR Newswire

Jul 15, 2021

08:42AM EDT Aeglea BioTherapeutics Appoints Jim Kastenmayer As General Counsel RTTNews

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

04:31PM EDT Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease PR Newswire

04:31PM EDT Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease Benzinga

Jul 8, 2021

08:34AM EDT Aeglea BioTherapeutics Appoints Jonathan Alspaugh As CFO RTTNews

08:32AM EDT Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer PR Newswire

Jun 24, 2021

08:39AM EDT Aeglea BioTherapeutics Doses First Patient In Phase 1/2 Clinical Trial Of AGLE-177 A Potential Treatment For Homocystinuria Benzinga

08:31AM EDT Aeglea BioTherapeutics Doses First Patient In Phase 1/2 Clinical Trial Of AGLE-177 For Homocystinuria RTTNews

08:30AM EDT Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of PR Newswire

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

Jun 22, 2021

08:32AM EDT Aeglea BioTherapeutics Appoints Marcio Souza To Board RTTNews

08:31AM EDT Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors PR Newswire

08:12AM EDT The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal Benzinga

Jun 2, 2021

08:20AM EDT The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements Benzinga

May 10, 2021

08:37AM EDT Aeglea BioTherapeutics Q1 EPS $(0.28) Up From $(0.57) YoY Benzinga

08:34AM EDT Aeglea BioTherapeutics Q1 Net Loss $18.2 Mln Vs. Net Loss $18.7 Mln Last Year RTTNews

08:31AM EDT Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and PR Newswire

May 6, 2021

08:30AM EDT Aeglea BioTherapeutics Launches THINK ARGININE(tm), a Disease Education PR Newswire

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 3, 2021

09:43AM EDT Aeglea Completes Patient Randomization For PEACE, Phase 3 Trial Of Pegzilarginase For Treatment Of Arginase 1 Deficiency RTTNews

08:37AM EDT Aeglea BioTherapeutics Completes Patient Randomization For PEACE, Its Pivotal Phase 3 Clinical Trial Of Pegzilarginase For Treatment Of Arginase 1 Deficiency Benzinga

08:31AM EDT Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency PR Newswire

Apr 1, 2021

04:30PM EDT Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in PR Newswire

Mar 22, 2021

08:47AM EDT Aeglea, Immedica In Commercialization Deal For Pegzilarginase For Treatment Of ARG1-D In Europe, Middle East RTTNews

08:39AM EDT UPDATE: Aeglea Will Receive $21.5M Upfront With Up To ~$130M In Milestone Payments And Royalties In The Mid-twenties Benzinga

08:38AM EDT Aeglea BioTherapeutics And Immedica Announce Commercialization Agreement For Pegzilarginase For The Treatment Of Arginase 1 Deficiency In Europe And Middle East Benzinga

08:31AM EDT Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East PR Newswire

Mar 18, 2021

08:52AM EDT Aeglea BioTherapeutics FY20 EPS $(1.52) vs $(2.45) In FY19 Benzinga

08:38AM EDT Aeglea BioTherapeutics Q4 Net Loss $22.7 Mln Vs $21.5 Mln Last Year RTTNews

08:30AM EDT Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial PR Newswire

Feb 24, 2021

04:30PM EST Aeglea BioTherapeutics Appoints Sara Brownstein to Board of Directors PR Newswire

Feb 3, 2021

04:33PM EST Aeglea BioTherapeutics Reports CFO, Charles York, To Leave Co.; Co. Has Initiated Search For Permanent Replacement; VP, Corporate Controller, Steven Weber, To Serve As Principal Accounting Officer Benzinga

04:30PM EST Aeglea BioTherapeutics Announces Transition of Chief Financial Officer PR Newswire

Jan 4, 2021

04:30PM EST Aeglea BioTherapeutics to Present at 39th Annual J.P. Morgan Healthcare PR Newswire

Dec 17, 2020

04:11PM EST Aeglea BioTherapeutics Appoints Alison Lawton To Board Of Directors RTTNews

Dec 1, 2020

07:37AM EST Aeglea BioTherapeutics Says FDA Granted Rare Pediatric Disease Designation To ACN00177 For Homocystinuria RTTNews

07:35AM EST Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation For ACN00177 For Homocystinuria RTTNews

07:31AM EST Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation For ACN00177 For The Treatment Of Homocystinuria Benzinga

07:30AM EST Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for PR Newswire

Nov 24, 2020

04:41PM EST Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor PR Newswire

Nov 17, 2020

04:31PM EST Aeglea BioTherapeutics To Participate In Two Upcoming Virtual Investor Conferences Nov. 23 And Dec. 1 Benzinga

04:30PM EST Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor PR Newswire

Nov 9, 2020

06:10AM EST HC Wainwright & Co. Maintains Buy on Aeglea BioTherapeutics, Lowers Price Target to $15 Benzinga

Nov 5, 2020

08:44AM EST Aeglea BioTherapeutics Q3 Loss/shr $0.29 Vs. Loss/shr $0.66 Prior Year RTTNews

08:34AM EST Aeglea BioTherapeutics Q3 EPS $(0.26) Up From $(0.66) YoY Benzinga

08:30AM EST Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and PR Newswire

Oct 26, 2020

04:40PM EDT Aeglea BioTherapeutics 13G Filing From Point72 Shows 6.2% Stake In Co. Benzinga

08:38AM EDT Aeglea BioTherapeutics Announces U.S., EU Orphan Drug Designations For ACN00177 RTTNews

08:35AM EDT CORRECTION: Granite Wins 2 Airport Projects In Alaska And California Totaling $15M; Ticker For Granite Is 'GVA' Benzinga

08:33AM EDT Granite Awarded Two Airport Projects In Alaska And California Totaling $15 Million Benzinga

08:33AM EDT Aeglea BioTherapeutics Announces US And EU Orphan Drug Designations For ACN00177 For Treatment Of Homocystinuria Benzinga

08:30AM EDT Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for PR Newswire

Oct 23, 2020

06:22AM EDT Aeglea Biotherapeutics Received FDA Orphan Drug Designation on October 23 for Treatment of Homocystinuria Benzinga

Oct 5, 2020

04:31PM EDT Aeglea BioTherapeutics Announces Presentation On Arginase 1 Deficiency And Homocystinuria Programs At Two Upcoming Virtual Medial Meetings Benzinga

04:30PM EDT Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and PR Newswire

Sep 2, 2020

04:05PM EDT Aeglea BioTherapeutics to Participate in September Investment GlobeNewswire Inc

Aug 18, 2020

04:05PM EDT Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in two presentations at the World Orphan Drug Congress USA 2020 being held virtually August 24-27, 2020. GlobeNewswire Inc

Aug 10, 2020

08:49AM EDT Aeglea BioTherapeutics Q2 EPS $(0.40) Beats $(0.44) Estimate Benzinga

08:30AM EDT Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at56 Week Analysis of Phase 1/2 Open-Label Extension Study GlobeNewswire Inc

Share